How to Get Finasteride in District of Columbia

Finasteride is an oral 5-alpha-reductase inhibitor sold as the brand Propecia at a 1 mg dose for male-pattern hair loss (androgenetic alopecia, AGA) and as the brand Proscar at a 5 mg dose for benign prostatic hyperplasia (BPH). Generic finasteride tablets are widely available at both strengths. It is prescription-only in every US state, including DC, so no legitimate pathway lets a resident buy it without a clinician's evaluation. The three realistic ways to get a prescription in DC are a licensed telehealth visit, an in-person visit with a primary care clinician, dermatologist, or urologist, and, for compounded or custom formulations, a DC-licensed 503A pharmacy filling a prescription a clinician has already written.

The direct answer and its boundary

A licensed DC-based or DC-authorized telehealth clinician (MD, DO, NP, or PA) can legally prescribe finasteride 1 mg for AGA after a remote history-based evaluation, without an in-person exam or mandatory labs, because AGA diagnosis is clinical rather than lab-dependent. Finasteride 5 mg for BPH is different: most prescribers want a recent PSA and basic urinary symptom history first, because finasteride lowers PSA and a baseline value is needed to interpret future readings. This distinction, not the mode of the visit, is the main gate to fast access. Coverage, PSA-testing requirements, and Medicaid prior-authorization rules can change and should be verified against the specific plan or pharmacy on the date of the visit.

What finasteride is approved for, and what is off-label

The FDA approved finasteride 1 mg (Propecia) for male-pattern hair loss and finasteride 5 mg (Proscar) for symptomatic BPH; both are older approvals and the drug has been generic for years. FDA drug approval database

Topical finasteride, low-dose oral minoxidil, and finasteride use in transgender or gender-diverse patients on feminizing hormone regimens are all off-label uses. A recent review of hair-loss therapeutics in transgender and gender-diverse populations discusses finasteride's role as an adjunct to estrogen therapy, but notes the evidence base for this population is limited and largely observational; anyone considering this route should discuss it explicitly with a clinician experienced in gender-affirming care rather than assuming standard AGA dosing applies. Androgenetic alopecia in transgender and gender diverse populations

Compounded topical finasteride, discussed below, is also off-label and unapproved as a distinct product; it is a pharmacist-prepared preparation made under a valid prescription, not an FDA-approved formulation.

DC telehealth prescribing: what is established and what needs a current check

DC permits telehealth as a valid basis for a prescriber-patient relationship, and multiple national platforms operate in the district. What a specific platform requires (photos, questionnaires, video visit) and how quickly it turns around a prescription varies by company and changes over time; this page does not attempt to rank platforms or promise a specific turnaround, since that is a business practice rather than a regulatory fact.

What is stable: the clinician must hold an active DC license appropriate to their role, and the same clinical logic applies regardless of whether the visit is virtual or in person. A valid finasteride prescription requires documentation of the indication, a review of contraindications (see below), and counseling on possible sexual side effects.

Who can prescribe finasteride in DC

Physicians (MD/DO) with a full DC medical license can prescribe without supervision. Nurse practitioners' and physician assistants' scope of practice, including whether NP practice is fully independent in DC, is set by DC statute and can be amended; if this distinction matters to your care plan, verify current scope-of-practice rules with the DC Department of Health Board of Medicine or Board of Nursing rather than relying on a general summary.

In-person options

Dermatologists most commonly manage AGA prescribing and monitoring; urologists and primary care clinicians most commonly manage BPH. Urgent care clinics generally do not prescribe finasteride, since neither AGA nor BPH is an urgent condition. Appointment wait times for primary care and dermatology in DC vary by practice and season; general national survey data on wait times exist but a precise DC-specific number is not something this page can confirm, so plan for it to take longer than a telehealth visit rather than relying on a specific day count.

What workup is needed before starting

For AGA (1 mg), diagnosis is clinical, typically staged with the Hamilton-Norwood scale; published dermatology guidance does not require baseline labs before starting. For BPH (5 mg):

• A baseline serum PSA is standard practice before starting, because finasteride reduces PSA levels and a pre-treatment baseline is needed to interpret future results.
• A urinalysis to exclude infection or hematuria is commonly obtained.
• A symptom score (IPSS) and, in some cases, a post-void residual measurement help establish severity and guide follow-up, at the treating clinician's discretion.

Exact PSA and prostate-volume thresholds used to decide who is a good candidate for a 5-alpha-reductase inhibitor come from urology guideline literature; a reader who wants the precise numeric thresholds behind a specific prescribing decision should ask the prescribing urologist to walk through the current guideline criteria rather than rely on a number reproduced secondhand here.

Verification checklist: stable facts vs. facts that change

Use the left two columns for what a reader can treat as background fact. Use the right two columns as an active checklist before finalizing a prescription or fill, since insurer rules, license status, and prices are the parts most likely to be stale by the time this page is read.

How long it typically takes

Telehealth intake, clinician review, and e-prescribing can be fast when there is no BPH lab requirement outstanding, but exact turnaround depends on the specific platform or practice and is not something this page can guarantee. In-person specialist and primary care appointment availability varies by practice; call ahead or check a scheduling portal for a real wait time rather than assuming a fixed number of days.

Cost and Medicaid coverage

Generic finasteride is inexpensive relative to many prescription drugs and is stocked at most DC-area retail and mail-order pharmacies, but this page does not state a specific price because cash prices change frequently and vary by pharmacy, quantity, and any discount card used. Check a current price-comparison tool or call the pharmacy directly.

DC Medicaid programs generally cover FDA-approved drugs used for approved indications, subject to the plan's own formulary and prior-authorization rules, which can change. Medicaid.gov DC state overview Medicaid.gov benefits overview Whether DC Medicaid currently requires prior authorization for finasteride, what ICD-10 codes or clinical criteria it wants documented, and how long a decision takes are all details that should be confirmed with the plan directly at the time of the request rather than assumed from a general description, since Medicaid formularies and PA criteria are revised over time and are not reliably summarized by secondary sources.

Most commercial plans cover generic finasteride at a standard generic-drug copay tier; brand-name Propecia prescribed for hair loss is frequently treated as a cosmetic exclusion. Confirm the specific plan's rule before assuming coverage.

Compounded and topical finasteride

DC-licensed 503A pharmacies may compound a patient-specific finasteride preparation, such as a topical solution or a nonstandard dose strength, when a valid prescription exists. The FDA's 503A framework requires a patient-specific prescription and prohibits large-scale, non-patient-specific distribution by a compounding pharmacy. FDA compounding laws and policies

Topical finasteride has been studied in small trials suggesting it can lower scalp DHT with less effect on serum DHT than the oral tablet, which is the rationale some clinicians give for offering it to patients bothered by systemic side effects. This remains an off-label, compounded option without an FDA-approved topical finasteride product, and the trial evidence behind specific percentage claims is limited in size; anyone considering it should ask the prescribing clinician to walk through what the supporting studies actually showed rather than relying on a single number. Confirm that any compounding pharmacy holds an active DC Board of Pharmacy license before filling.

Transferring an existing prescription into DC

Finasteride is not a DEA-scheduled controlled substance, so a DC pharmacy can generally accept a one-time transfer of remaining refills from an out-of-state pharmacy, following the pharmacy's standard non-controlled-substance transfer process. If no refills remain, the patient needs a new prescription, which a same-day telehealth visit can typically provide. Multi-state mail-order pharmacies can often continue shipping to a DC address on an existing prescription without a new one, provided refills remain and the original prescriber's license is still active in their home state.

Side effects, contraindications, and monitoring

The best-known adverse effects of finasteride are sexual: some men on 1 mg report erectile dysfunction, decreased libido, or ejaculation problems, at rates that trials have found are low in absolute terms but higher than placebo. A minority of men report that these symptoms persist after stopping the drug, a pattern sometimes called post-finasteride syndrome. This is an area of active pharmacovigilance rather than settled science; the FDA's MedWatch adverse-event system collects these reports for ongoing safety monitoring. FDA MedWatch A postmarketing case series specifically examined reports of suicide and suicidal ideation associated with finasteride use; it is a signal-detection case series, not a controlled study establishing causation, and its findings should be discussed with a prescriber rather than used to self-diagnose a risk level. Finasteride and Suicide: A Postmarketing Case Series Anyone experiencing new mood changes, suicidal thoughts, or persistent sexual dysfunction while on or after finasteride should contact their prescriber promptly, and anyone in crisis should seek urgent care or call 988.

Finasteride is contraindicated in pregnancy. Women who are or may become pregnant should not handle crushed or broken tablets because of the risk to a male fetus from dermal absorption; this warning appears on the FDA label and should be communicated at the point of prescribing. FDA finasteride label

For men on 5 mg, PSA is typically rechecked some months after starting to establish a new post-treatment baseline and then periodically thereafter; a PSA that does not fall as expected, or that rises from its new baseline, is a reason for urology follow-up rather than reassurance. Routine liver function testing is not required by the FDA label or major guidelines, since hepatotoxicity is not an established class effect at approved doses.

Combining with minoxidil

Finasteride and minoxidil work by different mechanisms, DHT suppression versus a vasodilatory effect that prolongs the hair growth phase, and many DC prescribers use them together off-label for AGA, including low-dose oral minoxidil as an alternative to the topical form. This combination is not an FDA-approved fixed-dose product. Specific percentage improvements reported in individual trials vary by study design and population; ask the prescribing clinician which trial evidence they are relying on rather than treating any single number as generalizable to your case.

Evidence boundary

Established: finasteride's FDA-approved indications and doses, its pregnancy contraindication, its effect of lowering PSA, and the basic mechanism of DHT suppression.

Plausible but not fully settled: the magnitude of benefit from combining finasteride with minoxidil, the comparative side-effect profile of topical versus oral finasteride, and the prevalence and mechanism of persistent post-discontinuation symptoms.

Not established from the material available for this page: specific DC Medicaid prior-authorization timelines, specific dollar figures for cash price or copay, specific appointment wait times in DC, and precise numeric trial results that would require checking the primary paper rather than a secondary description.

Getting started, in order

1. Decide whether your need is AGA or BPH; this determines whether labs come first.
2. For AGA, a telehealth visit with a DC-licensed clinician is usually the fastest legitimate path.
3. For BPH, get a recent PSA and basic urinary symptom history before or during the visit.
4. Choose a DC-licensed retail or mail-order pharmacy for a standard tablet, or a licensed 503A pharmacy if a compounded formulation is medically appropriate.
5. Confirm your specific insurance plan's coverage and any prior-authorization requirement before assuming a copay amount.
6. Follow up with the prescribing clinician at the interval they recommend to assess hair or symptom response and to recheck PSA if applicable.

When to seek care sooner than a routine follow-up

Contact the prescriber promptly for new or worsening urinary retention, blood in the urine, signs of an allergic reaction, new depression or suicidal thoughts, or sexual side effects that are distressing. Seek urgent or emergency care for inability to urinate, severe flank pain, or any suicidal crisis; call 988 or go to an emergency department for a mental health emergency.

References

1. U.S. Food and Drug Administration. Finasteride (Propecia/Proscar) approval and label information. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020788
2. U.S. Food and Drug Administration. Compounding laws and policies (503A). https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
3. U.S. Food and Drug Administration. MedWatch safety information and adverse event reporting. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
4. Medicaid.gov. District of Columbia state overview. https://www.medicaid.gov/state-overviews/stateprofile.html?state=dc
5. Medicaid.gov. Medicaid benefits overview. https://www.medicaid.gov/medicaid/benefits/index.html
6. Androgenetic alopecia in transgender and gender diverse populations: A review of therapeutics. https://pubmed.ncbi.nlm.nih.gov/34756934/
7. Finasteride and Suicide: A Postmarketing Case Series. https://pubmed.ncbi.nlm.nih.gov/31935720/